anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R.
Armuzzi A, et al. Among authors: chimenti s.
Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1 Suppl):11-32. doi: 10.1177/03946320140270S102.
Int J Immunopathol Pharmacol. 2014.
PMID: 24774504
Free article.
Review.